文献速递真菌感染细菌感染、耐药与抗菌药物

泊沙康唑与olorofim在侵袭性肺曲霉病小鼠模型中呈拮抗相互作用

Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

本研究在中性粒细胞减少小鼠侵袭性肺曲霉病模型中,以半乳甘露聚糖为药效学终点,评估olorofim与泊沙康唑单用及联用的药效学。结果显示,对三唑敏感株两药单用均抑制半乳甘露聚糖,但联用抑制效果低于单用预期;对三唑耐药株,olorofim单用有抑制而泊沙康唑单用无抑制,联用抑制低于olorofim单用。交互模型揭示拮抗性药效学交互参数,蒙特卡洛模拟预测联合治疗在野生型感染中仍有净获益,但在三唑耐药感染中疗效可能欠佳。

要点

  • 泊沙康唑在体内降低olorofim对曲霉的药效,呈拮抗作用。
  • 三唑敏感株感染中两药联用抑制半乳甘露聚糖低于单用预期。
  • 三唑耐药株感染中联用效果低于olorofim单用,泊沙康唑贡献极小。

核心结论

  • 泊沙康唑在体内降低olorofim的药效,两者呈拮抗性药效学交互。
  • 联合治疗对野生型曲霉感染仍有净获益,但对三唑耐药感染可能次优。

研究设计与样本

  • 中性粒细胞减少小鼠侵袭性肺曲霉病模型,使用野生型及三唑耐药烟曲霉株。
  • 以半乳甘露聚糖为药效学终点,评估olorofim与泊沙康唑单用及联用,并拟合药效学交互模型。
  • 进行人体样给药方案的蒙特卡洛模拟以外推至临床。

主要发现

  • 三唑敏感株:两药单用均抑制半乳甘露聚糖,联用抑制低于单用预期。
  • 三唑耐药株:olorofim单用抑制半乳甘露聚糖而泊沙康唑单用不抑制,联用抑制低于olorofim单用。
  • 交互模型显示拮抗性药效学交互参数值。
  • 人体药代动力学外推预测联合治疗对烟曲霉感染仍有净获益,但三唑耐药感染疗效降低。

临床怎么用

  • olorofim与具抗霉活性的三唑联用对野生型感染可能有效。
  • 在三唑耐药感染中,三唑对药效贡献极小且拮抗olorofim,联合可能次优。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Olorofim is a new antifungal agent with a novel mechanism of action with in vitro activity against Aspergillus fumigatus and other clinically important moulds. As antifungal combinations are of interest to extend the spectrum of coverage and improve antifungal activity, we investigated the pharmacodynamics of olorofim in combination with posaconazole. METHODS: Using galactomannan as a pharmacodynamic endpoint, olorofim and posaconazole were assessed alone and in combination in a neutropenic murine model of pulmonary aspergillosis using wild-type and triazole-resistant strains of A. fumigatus. Pharmacokinetic and pharmacodynamic data were fitted to a pharmacodynamic interaction model. Monte Carlo simulations of human-like regimens of both agents alone and in combination were performed to extrapolate to clinical settings. RESULTS: With the triazole-susceptible isolate, both monotherapy arms suppressed galactomannan, but suppression with the combination was less than expected from the monotherapy arms. With the triazole-resistant isolate, monotherapy produced galactomannan suppression with olorofim but not posaconazole; the combination arm produced less suppression than olorofim alone. The interaction model revealed antagonistic pharmacodynamic interaction parameter values. Extrapolations to human pharmacokinetics predicted that combination therapy would still have a net beneficial effect in A. fumigatus infections, albeit with reduced efficacy in infections with triazole-resistant isolates. CONCLUSIONS: Posaconazole reduces the effect of olorofim in vivo. A combination of olorofim and a mould-active triazole is likely efficacious in wild-type infections but may be suboptimal in triazole resistance infections where there is minimal contribution of the mould-active triazole to antifungal activity and the triazole antagonises olorofim to produce a submaximal effect.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Darlow CA, Farrington N, Märtson AG, et al. Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis. J Antimicrob Chemother. 2025. PMID: 40990169. doi:10.1093/jac/dkaf355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。